Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

Figure 4

Summary intervention effects from network meta-analysis for objective response rate and 6 months progression-free survival in the PIK3CA-mutated subgroup and the PIK3CA-mutated and wild-type total subgroup patients with breast cancer according to SUCRA score.